Pharmaceutical Intermediates Ethyl 2-Amino-1,3-Thiazole-4-Carboxylate Cas No: 5398-36-7

A heterocyclic building block central to the industrial synthesis of third-generation cephalosporin antibiotics, Ethyl 2-Amino-1,3-Thiazole-4-Carboxylate (CAS 5398-36-7) functions as a masked glycinyl synthon in acylation cascades. The compound presents as a white to off-white crystalline powder with a molecular weight of 172.20 g·mol⁻¹ (C₆H₈N₂O₂S) and a characteristic melting endotherm onset recorded by DSC at 170–174 °C when purity exceeds 99.0%. Its commercial availability spans technical-grade material (≥98.0% by HPLC, area normalization) through micronized, low-endotoxin variants qualified against ICH Q3C residual solvent limits for ceftriaxone sodium sterile bulk manufacturing. Because the exocyclic amine at C-2 activates the thiazole ring toward electrophilic attack while the ethyl carboxylate at C-4 moderates electron density, the intermediate delivers regioselective N-acylation without the competing S-alkylation observed with non-esterified 2-aminothiazole. Production-scale campaigns at 100–500 kg batch sizes consistently demonstrate that moisture ingress above 0.3% Karl Fischer titration accelerates dimerization during storage, necessitating double polyethylene-lined fibre drums with desiccated silica gel packets and a recommended retest interval of 12 months at 2–8 °C.

Purity Specification and Chromatographic Fingerprint
Quality control protocols for bulk material released to cGMP intermediate manufacturing conform to the monograph-style criteria embedded in supplier dossiers filed with Type II drug master files. A representative release specification appears in Table 1. Forced degradation studies conducted in-house by several API manufacturers reveal that the primary process-related impurity, Ethyl 2-amino-5-chlorothiazole-4-carboxylate, elutes at a relative retention time of 1.32 on a C18 column (Inertsil ODS-3, 250 × 4.6 mm, 5 µm, mobile phase 0.1% trifluoroacetic acid/acetonitrile gradient). Its concentration is controlled to ≤0.50% because residual halogen at the C-5 position introduces mutagenic structural alerts requiring purging calculations per ICH M7 Option 4.


Table 1 – Batch Release Specification (Typical)
Parameter
Acceptance Criterion
Test Method
Assay (anhydrous)
98.0–102.0%
HPLC, external standard, 254 nm
Melting Range
168–175 °C
USP <741> Class I capillary
Water Content
≤0.30%
Karl Fischer coulometry
Residue on Ignition
≤0.10%
USP <281>, 2 g sample
Heavy Metals*
≤10 ppm
USP <231> Method II
Single Unknown Impurity
≤0.15%
HPLC, area %
Total Impurities
≤2.0%
HPLC, area %

*Elemental impurity control is transitioning to USP <232/233>; Pd and Cu catalysts used in synthesis routes are verified below PDE limits by ICP-MS on every tenth production lot.

When the ethyl 2-amino-1,3-thiazole-4-carboxylate solid is comminuted to a particle size D₉₀ below 50 µm via air-jet milling, specific surface area measured by BET nitrogen adsorption can exceed 1.8 m²·g⁻¹. This micronized grade dissolves rapidly in dimethylacetamide at −10 °C, a requirement for low-temperature mixed-anhydride activation with pivaloyl chloride prior to coupling with 7-aminocephalosporanic acid (7-ACA). Process analytical technology (PAT) deployments on pilot-plant reactors monitor the dissolution endpoint via focused beam reflectance measurement (FBRM), observing chord length distributions shifting from 30–300 µm to <10 µm within 15–20 minutes under 400 rpm pitched-blade impeller agitation.

Does the ethyl ester outperform methyl or benzyl congeners in aminothiazole acylation?
Selecting the optimal ester protecting group is governed by the interplay of steric demand, crystallinity of acylated intermediates, and susceptibility to deprotection under downstream hydrogenolysis or enzymatic conditions. Methyl 2-amino-1,3-thiazole-4-carboxylate (CAS 2564-22-9) provides a lower molecular weight (158.18 g·mol⁻¹) and faster reaction kinetics; however, the resulting methoxycarbonyl intermediates exhibit poor crystallinity in tert-butyl methyl ether/heptane antisolvent systems, complicating isolation in > 99.5% purity by simple filtration. Industrial isolation of ceftizoxime sodium intermediates favours the ethyl ester because the precipitated acylated derivative forms compact orthorhombic crystals with a bulk density of 0.45–0.55 g·cm⁻³, amenable to centrifugal drying without fracture. In contrast, benzyl 2-amino-1,3-thiazole-4-carboxylate, while readily cleavable by hydrogenolysis, introduces a benzylic chromophore that complicates UV monitoring during preparative HPLC and can generate toluene as a genotoxic impurity requiring dedicated solvent swaps. A head-to-head comparison of key process fitness attributes is given in Table 2.


Table 2 – Comparative Process Fitness of Thiazole Ester Derivatives
Attribute
Ethyl Ester (5398-36-7)
Methyl Ester
Benzyl Ester
Crystallinity of N-acylated 7-ACA adduct
High; orthorhombic, Tm >200 °C
Low; amorphous precipitates
Moderate; monohydrate forms
Deprotection Method
NaOH/acetone, 0–5 °C, 2 h
NaOH/MeOH, rapid but exothermic
H2/Pd-C, 40 psi
Genotoxic Risk
Ethanol (Class 3 solvent)
Methanol (Class 2, <3000 ppm)
Toluene (Class 2, requires control)
Bulk Stability, 25 °C/60% RH
>24 months
12 months (hygroscopic)
18 months (photo-sensitive)
Cost Index (relative, per kg)
1.0
0.7
2.3

Published data for direct comparative reactivity with chloroacetyl chloride in dichloromethane at −5 °C indicates that the ethyl ester derivative acylates with an observed second-order rate constant (kobs) approximately 1.4 × 10⁻³ L·mol⁻¹·s⁻¹, only 15% slower than the methyl ester, yet the work-up yield of isolated product is 12–18% higher due to reduced aqueous solubility losses. This trade-off routinely justifies the incremental cost in cephalosporin manufacturing economics models assuming >90% overall yield from solid bulk intermediate to final sterile API.

Processing Window for 7-ACA Side-Chain Introduction
Virtually every synthetic route to cefotaxime, ceftizoxime, and ceftriaxone relies on condensation of the activated thiazole carboxylate with the free amine of the β-lactam nucleus. A common manufacturing protocol employs ethyl 2-amino-1,3-thiazole-4-carboxylate suspended in methylene chloride at −15 to −10 °C with 1.05 equivalents of triethylamine, then treated with 1.02 equivalents of pivaloyl chloride to form a mixed anhydride. The activation exotherm must be controlled to maintain the jacket setpoint at −20 ± 3 °C because excursions above −5 °C lead to symmetrical anhydride formation detectable as a second eluting peak at RRT 0.85. When the activated solution is transferred into a precooled solution of 7-ACA silyl ether in dichloromethane, the coupling completes within 45 minutes as monitored by inline ReactIR tracking the carbonyl stretch shift from 1820 cm⁻¹ to 1785 cm⁻¹. Yield losses in this step arise primarily from β-lactam ring opening if residual water exceeds 200 ppm in the solvent train; therefore, molecular sieve drying columns are recirculated for a minimum of 8 hours prior to use.

Batch-to-batch variability in the ethyl 2-amino-1,3-thiazole-4-carboxylate colour (APHA values above 50 for a 10% w/v solution in methanol) can propagate to coloured final API, risking compliance with EP 2.2.2 Degree of Coloration limits. Decolourising carbon treatment of the thiazole intermediate in refluxing ethanol followed by hot filtration through 0.45 µm PTFE membrane cartridges reduces APHA to <20 and additionally scavenges trace palladium leached from earlier Hantzsch thiazole cyclisation steps. Operators report that extended treatment beyond 2 hours increases the ethyl ester transesterification with ethanol solvent, generating the ethyl ester-ethyl ester exchange product detectable at levels up to 0.8%.

When this intermediate is employed in 7-ACA derivatization, competing nucleophilic pathways must be suppressed. The C-2 amine can attack the activated β-lactam carbonyl in an intermolecular fashion if the local stoichiometric ratio deviates; maintaining a 10–15% molar excess of the pre-activated thiazole mixed anhydride relative to 7-ACA ensures pseudo-first-order acylation. Furthermore, trace moisture hydrolyses pivaloyl chloride to pivalic acid, which forms a stable ammonium salt with triethylamine and creates an organic-aqueous emulsion during the subsequent bicarbonate wash, extending phase separation times beyond 30 minutes. These operational boundaries are codified in the process control strategy submitted under ICH Q11 sections 3.1.3 (critical process parameters) and 3.2.1 (in-process controls).

Stability-Limiting Degradation Routes
Forced degradation profiling in accordance with ICH Q1A(R2) identifies three principal routes. Hydrolytic ring opening of the thiazole heterocycle occurs under strongly acidic conditions (refluxing 1 M HCl, 24 h), yielding thiourea derivatives and ethyl pyruvate identified by LC-MS with a mass ion at m/z 117.1. Alkaline degradation (0.1 M NaOH, 40 °C, 4 h) saponifies the ethyl ester to the carboxylic acid (CAS 2150-55-2) while leaving the thiazole ring intact; this acid is a competent intermediate for subsequent penicillin G acylase-mediated coupling but exhibits severely reduced solubility in dichloromethane, requiring a switch to DMF/H₂O solvent mixtures that complicate product isolation. Photolytic exposure per ICH Q1B Option 2 (1.2 million lux-hours visible, 200 Wh·m⁻² UV) produces a pale-yellow discolouration and a photodimer impurity with molecular ion [M+H]⁺ at m/z 343.3 in the LC-MS chromatogram; this is suppressed by amber glass packaging or opaque HDPE containers. Manufacturers integrating this intermediate into continuous flow platforms have demonstrated that a residence time of 120 seconds at −5 °C in a Corning Advanced-Flow reactor completely suppresses the photochemical pathway when combined with a 405 nm UV-filtering module inline, an advantage over batch stirred-tank processing subject to ambient laboratory lighting.

Regulatory Status and Pharmacopoeial Alignment
Although no dedicated pharmacopoeial monograph exists for this non-sterile intermediate, its quality attributes are profiled against USP <1086> Impurities in Official Articles and Ph. Eur. General Chapter 5.10 for control of impurities in substances for pharmaceutical use. Suppliers maintain ISO 9001:2015 and ISO 14001:2015 certifications, with REACH registration covering the 1–10 tonne per annum band under EC No. 458-770-5. Residual solvent analysis employs a headspace GC-FID method validated per ICH Q2(R1) for quantitation of ethanol (≤5000 ppm, Class 3), acetone (≤5000 ppm), and dichloromethane (≤600 ppm, Class 2). Transition metal analysis by ICP-MS quantifies Pd (≤10 ppm), Cu (≤50 ppm), and Fe (≤20 ppm) against USP <232> oral PDE limits, justified by the intermediate’s position early in the synthetic route with subsequent purging factors above 10⁴ for the final crystallisation of the sterile cephalosporin sodium salt.

The compound is classified as Acute Toxicity Category 4 (oral) according to GHS criteria, requiring engineering controls for dust containment when handling quantities exceeding 5 kg. Occupational exposure limits in the absence of a substance-specific OEL are set at 0.5 mg·m⁻³ (inhalable fraction) based on the default pharmaceutical compound banding approach described in the ISPE Good Practice Guide on Occupational Health. Personnel handling open powder in downflow booths record no instances of dermal sensitisation when using nitrile gloves with a breakthrough time exceeding 480 minutes as per EN 374-3 testing against saturated aqueous solutions. A supplier-maintained nitrosamine risk assessment, conducted in alignment with EMA/409815/2020, confirms the absence of secondary amine functionalities, nitrite sources, or acidic nitrosation conditions during manufacture, thus placing the intermediate in the “negligible nitrosamine formation potential” category without requirement for confirmatory testing of every batch.